IDH野生型弥漫性星形细胞瘤(NEC)的临床分子特征与预后因素
该回顾性研究纳入46例IDH野生型弥漫性星形细胞瘤(NEC)患者,分析临床、分子、影像及切除程度与总生存的关系。中位OS为45.0个月(95% CI 27.7–62.4)。多因素分析显示年龄较大、Ki-67指数较高及非全切为不良OS的独立预测因素;Ki-67≥5的患者加用替莫唑胺辅助治疗有生存获益。
要点
- 最大安全切除与Ki-67指数对该肿瘤预后有重要价值。
- 年龄较大、Ki-67较高、非全切为不良OS独立预测因素。
- Ki-67≥5患者加用替莫唑胺辅助治疗有生存获益。
核心结论
- 支持最大安全切除的重要性及Ki-67指数的预后价值。
- KIT、PDGFRA扩增和ATM突变与Ki-67指数升高相关,针对这些改变的靶向治疗值得进一步研究。
研究设计与样本
- 回顾性图表与影像审查研究,纳入46例组织学2级和3级IDH野生型弥漫性星形细胞瘤(NEC)患者。
- 收集临床、组织病理、分子标志物、MRI表现及切除程度数据,对总生存(OS)进行单因素和多因素Cox分析。
主要发现
- 中位OS为45.0个月(95% CI 27.7–62.4)。
- 多因素分析显示诊断时年龄较大(HR=1.10,P=0.007)、Ki-67指数较高(HR=1.09,P=0.002)及非全切(HR=3.57,P=0.042)为不良OS的独立预测因素。
- KIT扩增(P=0.024)、PDGFRA扩增(P=0.034)和ATM突变(P=0.050)的肿瘤显示Ki-67指数升高。
- 组织学级别较高(P<0.001)和MRI上浸润性表现(P=0.029)的肿瘤也显示Ki-67指数升高。
- Ki-67指数≥5的患者中,加用替莫唑胺辅助治疗带来生存获益(P=0.014)。
关键数值与推荐
- 中位OS:45.0个月(95% CI 27.7–62.4)。
- 不良OS独立预测因素:年龄较大HR=1.10(P=0.007),Ki-67较高HR=1.09(P=0.002),非全切HR=3.57(P=0.042)。
- Ki-67≥5患者加用替莫唑胺辅助治疗有生存获益(P=0.014)。
临床怎么用
- 对此类肿瘤应争取最大安全切除。
- 评估Ki-67指数有助于预后分层。
- Ki-67≥5的患者可考虑加用替莫唑胺辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The clinical nature of IDH-wildtype astrocytoma, not elsewhere classified (NEC), is poorly understood. To this end, we aimed to investigate the clinical, molecular, imaging, and prognosis of histological grade 2 and 3 IDH-wildtype diffuse astrocytoma, NEC. METHODS: Retrospective chart and imaging reviews were performed for 46 patients with IDH-wildtype diffuse astrocytoma, NEC. Data regarding clinical, histopathological, molecular markers, MRI findings, and the extent of resection were collected. Univariable and multivariable Cox analyses were performed for overall survival (OS). RESULTS: The median OS was 45.0 months (95% CI 27.7–62.4). Multivariable analysis identified older age at diagnosis (hazard ratio [HR] = 1.10, P = 0.007), higher Ki-67 index (HR = 1.09, P = 0.002), and non-gross total resection (HR = 3.57, P = 0.042) as independent predictors of unfavorable OS. Tumors with genetic alterations such as amplification of KIT (P = 0.024) and PDGFRA (P = 0.034), and mutations in ATM (P = 0.050) showed an increased Ki-67 index. Tumors with higher histological grade (P < 0.001) and infiltrative appearance on MRI (P = 0.029) also showed an increased Ki-67 index. For patients with Ki-67 index ≥ 5, addition of adjuvant temozolomide therapy resulted in a survival benefit (P = 0.014). CONCLUSION: Our findings support the importance of maximal safe resection and prognostic value of the Ki-67 index in this tumor. KIT, PDGFRA amplification and ATM mutations were associated with the increased Ki-67 indices, and targeted therapies against these alterations warrant further investigation.
引用
- Cho WJ, Choi K, Han K, et al. Clinical and molecular characteristics and prognostic factors of diffuse astrocytoma, IDH-wildtype, not elsewhere classified. J Neurooncol. 2025. PMID: 41324809. doi:10.1007/s11060-025-05358-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。